GlassScriptPhysician profile
Shalaka D Indulkar
NPI 1194919514
$18,595.99
in general payments reported to CMS, 2019-2025
49 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,158 · 2020: $1,491 · 2021: $3,347 · 2022: $2,657 · 2023: $2,502 · 2024: $3,706 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,866 · Education: $75.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,866.31 |
| Education | $75.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,464.52 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $2,276.37 | 2020-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $2,274.55 | 2019-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Jazz Pharmaceuticals INC. | $2,079.09 | 2019-2025 | |
| Tris Pharma INC | $882.81 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Aquestive Therapeutics, INC. | $774.40 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $770.40 | 2019-2024 | Jornay Pm |
| Eisai INC. | $762.28 | 2019-2023 | |
| Corium, LLC | $486.03 | 2022-2025 | Azstarys |
| Catalyst Pharmaceuticals, INC. | $473.98 | 2023-2025 | Fycompa |
| Sk Life Science, INC. | $424.71 | 2021-2025 | |
| Greenwich Biosciences, INC. | $373.51 | 2019-2021 | |
| Aucta Pharmaceuticals, INC. | $371.63 | 2024-2025 | Motpoly Xr |
| Adlon Therapeutics L.P. | $313.56 | 2019-2021 | |
| Livanova USA, INC. | $300.54 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalaka Indulkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.